Ecnoglutide Demonstrates Significant and Sustained Weight Loss in Adults Without Diabetes

A recent clinical trial published in The Lancet Diabetes & Endocrinology highlights the promising effects of ecnoglutide, a novel cyclic adenosine monophosphate-biased GLP-1 receptor agonist, in promoting weight loss among adults with overweight or obesity without diabetes. The study was conducted to evaluate the efficacy and safety of once-weekly subcutaneous injections of ecnoglutide at doses of 1.2 mg, 1.8 mg, and 2.4 mg, compared to a placebo. Results showed that after 40 weeks, participants receiving ecnoglutide experienced substantial reductions in body weight, with the highest dose group achieving a 13.2% mean weight decrease, versus only 0.1% in the placebo group. Notably, 77% to 87% of patients on ecnoglutide achieved at least a 5% weight loss, a critical milestone for health improvement, compared to just 16% in the placebo group.

Adverse events were common across all groups, with 93% in the treatment arms and 84% in the placebo group experiencing treatment-emergent side effects. Despite this, ecnoglutide was generally well-tolerated, and its extended dosing flexibility offers a personalized approach for weight management. The study, supported by Hangzhou Sciwind Biosciences, suggests that ecnoglutide could become a potent therapeutic option for managing obesity in adults, contributing significantly to obesity treatment strategies.

This research underscores the potential of biased GLP-1 receptor agonists in weight management, providing a new avenue for those struggling with overweight and obesity without the complications of diabetes. The findings are part of an ongoing effort to develop effective, long-lasting treatments for obesity, which remains a major global health challenge.